Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Table 2

The quality assessment of included study using the Newcastle–Ottawa scale.

Study	Selection				Comparability		Outcome			TOTAL	Quality
	REC	SNEC	AE	DO	SC	AF	AO	FU	AFU
Hammer 2015	1	1	1	1	0	0	1	1	1	7	High
Obokata 2016	1	1	1	1	0	0	1	0	1	6	Moderate
Zhang 2017	1	1	1	1	0	0	1	0	1	6	Moderate
Gungor 2017	1	1	1	1	0	0	1	0	1	6	Moderate
Keddis 2017	1	1	1	1	0	0	1	0	1	6	Moderate
Tuegel 2018	1	1	1	1	0	0	1	0	1	6	Moderate
Homsak 2018	1	1	1	1	0	0	1	0	1	6	Moderate
Seo 2018	1	1	1	1	0	0	1	0	1	6	Moderate
Plawecki 2018	1	1	1	1	0	0	1	0	1	6	Moderate
Bansal 2019	1	1	1	1	0	0	1	1	1	7	High
Lamprea-Montealegre 2019	1	1	1	1	0	0	1	1	1	7	High
Feldreich 2019	1	1	1	1	0	0	1	1	1	7	High
Choi 2020	1	1	1	1	0	0	1	0	1	6	Moderate
Devine 2020	1	1	1	1	0	0	1	0	1	6	Moderate
Wang 2020	1	1	1	1	0	0	1	1	1	7	High

REC: representativeness of the exposed cohort; SNEC: selection of the nonexposed cohort; AE: ascertainment of exposure; DO: demonstration that outcome of interest was not present at start of study; SC: study controls for age and sex; AF: study controls for any additional factors (chemoradiotherapy, curative resection); AO: assessment of outcome; FU: follow-up long enough (36 M) for outcomes to occur; AFU: adequacy of follow-up of cohorts. “1” means that the study is satisfied the item, and “0” means the opposite situation.